{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:43:41Z","timestamp":1784180621024,"version":"3.55.0"},"reference-count":43,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Real-world data on the prevalence and burden of patients with chronic spontaneous urticaria (CSU) are limited in Japan. This study aimed to estimate CSU prevalence and assess its humanistic and economic burden. Methods: This analysis utilized data from Japanese adult respondents self-reporting physician-diagnosed CSU collected through the 2019 National Health and Wellness Survey. The weighted 12-month prevalence was estimated using 2018 international census projections. Outcomes included the SF-12v2 (physical and mental component summary [PCS and MCS] scores), health utility index (SF-6D and EQ-5D), Dermatology Life Quality Index (DLQI), Generalized Anxiety Disorder-7, Patient Health Questionnaire-9, Work Productivity and Activity Impairment scores at data collection, and healthcare resource utilization over the past 6 months. Results: Among 30,006 respondents, 334 reported having CSU, of whom 62.3% were female. The mean (SD) age at data collection and CSU diagnosis was 50.8 (15.3) and 39.2 (14.9) years, respectively. The weighted prevalence of CSU was 1.1%. The mean (SD) PCS and MCS scores were 50.3 (7.0) and 45.1 (10.0), respectively. The mean (SD) health utility measures (SF-6D and EQ-5D) were 0.71 (0.13) and 0.79 (0.18), respectively. The mean (SD) DLQI score was 3.8 (6.0). More than 40% of patients reported mild\/moderate\/severe anxiety and depression. The mean % (SD) scores for absenteeism, presenteeism, overall work impairment, and activity impairment were 7.6 (17.6), 27.2 (27.2), 30.3 (29.6), and 28.5 (27.8), respectively. Approximately 90.0% of patients visited healthcare providers, including emergency room visits (6.9%) and hospitalizations (9.9%). Conclusions: This study provides insights into the diagnosed prevalence and burden of CSU in Japan, highlighting its impact on patients\u2019 lives.<\/jats:p>","DOI":"10.3390\/jcm14041162","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:34:32Z","timestamp":1739252072000},"page":"1162","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevalence and Burden of Chronic Spontaneous Urticaria in Japan: A Cross-Sectional Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1569-6034","authenticated-orcid":false,"given":"Michihiro","family":"Hide","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hiroshima Citizens Hospital, Hiroshima 730-8518, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Uda","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K., Tokyo 105-6333, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuko","family":"Maki","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K., Tokyo 105-6333, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K., Tokyo 105-6333, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4450-066X","authenticated-orcid":false,"given":"Ravneet Kaur","family":"Kohli","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd., Hyderabad 500081, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaloo","family":"Gupta","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences, Austin, TX 78741, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Krupsky","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences, Austin, TX 78741, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Balkaran","sequence":"additional","affiliation":[{"name":"Oracle Life Sciences, Austin, TX 78741, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Magdalena","family":"Balp","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40257-015-0134-8","article-title":"Resource use and costs in an insured population of patients with chronic idiopathic\/spontaneous urticaria","volume":"16","author":"Broder","year":"2015","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.anai.2015.06.030","article-title":"Effect of chronic urticaria on US patients: Analysis of the National Health and Wellness Survey","volume":"115","author":"Vietri","year":"2015","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/bjd.16105","article-title":"Prevalence and incidence of chronic spontaneous urticaria in the entire Korean adult population","volume":"178","author":"Kim","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/bjd.14470","article-title":"Epidemiology of chronic spontaneous urticaria: Results from a nationwide, population-based study in Italy","volume":"174","author":"Lapi","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2340\/00015555-3104","article-title":"The prevalence of atopic dermatitis and chronic spontaneous urticaria are associated with parental socioeconomic status in adolescents in China","volume":"99","author":"Xiao","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/all.13209","article-title":"The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU","volume":"72","author":"Maurer","year":"2017","journal-title":"Allergy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/all.13430","article-title":"Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE-CSU","volume":"73","author":"Sussman","year":"2018","journal-title":"Allergy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/bjd.19561","article-title":"The global burden of chronic urticaria for the patient and society","volume":"184","author":"Bernstein","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_12","unstructured":"Ministry of Health, Labour and Welfare of Japan (2023, April 10). Patient Survey 2020. Available online: http:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/kanja\/10syoubyo\/index.html."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/1346-8138.16562","article-title":"A survey on subtypes and clinical characteristics of 1061 patients with urticaria in the primary care institutes in Japan","volume":"49","author":"Saito","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2332\/allergolint.10-OA-0182","article-title":"Impact of sedative and non-sedative antihistamines on the impaired productivity and quality of life in patients with pruritic skin diseases","volume":"59","author":"Murota","year":"2010","journal-title":"Allergol. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/1346-8138.14502","article-title":"Impact of chronic urticaria on quality of life and work in Japan: Results of a real-world study","volume":"45","author":"Itakura","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1346-8138.15630","article-title":"Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria","volume":"48","author":"Matsubara","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"A646","DOI":"10.1016\/j.jval.2012.08.262","article-title":"PRM11 Evidence for validity of a national patient-reported survey in Japan: The Japan National Health and Wellness Survey","volume":"15","author":"Dibonaventura","year":"2012","journal-title":"Value Health"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"A647","DOI":"10.1016\/j.jval.2012.08.263","article-title":"PRM12 Evidence for validity of a national patient-reported survey in China: The China National Health and Wellness Survey","volume":"15","author":"DiBonaventura","year":"2012","journal-title":"Value Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med. Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0895-4356(98)00109-7","article-title":"Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project. International Quality of Life Assessment","volume":"51","author":"Gandek","year":"1998","journal-title":"J. Clin. Epidemiol."},{"key":"ref_23","unstructured":"Ware, J., Kosinski, M., and Keller, S. (1995). SF-12: How to Score the SF-12 Physical and Mental Summary Scales, The Health Institute, New England Medical Center. [2nd ed.]."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J. Health Econ."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kontodimopoulos, N., Stamatopoulou, E., Gazi, S., Moschou, D., Krikelis, M., and Talias, M.A. (2022). A comparison of EQ-5D-3L, EQ-5D-5L, and SF-6D utilities of patients with musculoskeletal disorders of different severity: A health-related quality of life approach. J. Clin. Med., 11.","DOI":"10.3390\/jcm11144097"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s11136-013-0537-z","article-title":"Assessing the performance of the EQ-VAS in the NHS PROMs programme","volume":"23","author":"Feng","year":"2014","journal-title":"Qual. Life Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: What do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J. Investig. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: The GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: Validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.genhosppsych.2010.03.006","article-title":"The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: A systematic review","volume":"32","author":"Kroenke","year":"2010","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jad.2020.09.131","article-title":"Screening for depression in primary care with Patient Health Questionnaire-9 (PHQ-9): A systematic review","volume":"279","author":"Costantini","year":"2021","journal-title":"J. Affect. Disord."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"R177","DOI":"10.1186\/ar3141","article-title":"Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis","volume":"12","author":"Zhang","year":"2010","journal-title":"Arthritis Res. Ther"},{"key":"ref_36","unstructured":"U.S. Census Bureau (2023, April 10). International Database: World Population Estimates and Projections, Available online: https:\/\/www.census.gov\/programs-surveys\/international-programs\/about\/idb.html."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.alit.2017.10.001","article-title":"Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study","volume":"67","author":"Hide","year":"2018","journal-title":"Allergol. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/all.12078","article-title":"Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine","volume":"68","author":"Hiragun","year":"2013","journal-title":"Allergy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3904\/kjim.2022.078","article-title":"The burden of symptomatic patients with chronic spontaneous urticaria: A real-world study in Korea","volume":"37","author":"Ye","year":"2022","journal-title":"Korean J. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/1346-8138.14218","article-title":"Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey","volume":"45","author":"Arima","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1081-1206(10)60617-5","article-title":"Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria","volume":"99","author":"Ozkan","year":"2007","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2340\/00015555-1109","article-title":"High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria","volume":"91","author":"Staubach","year":"2011","journal-title":"Acta Derm. Venereol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/all.12068","article-title":"Psychosocial factors and chronic spontaneous urticaria: A systematic review","volume":"68","author":"Blinderman","year":"2013","journal-title":"Allergy"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1162\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:31:02Z","timestamp":1760027462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14041162"],"URL":"https:\/\/doi.org\/10.3390\/jcm14041162","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}